← Back to Patent Explorer
US5501949A Expired / Lapsed US ⏱️ 0.0 years remaining

Particle bound binding component immunoassay

Assignee: Murex Diagnostics Corp
•
Filing: 1994-08-15
•
Granted: 1996-03-26
•
Expires: 2014-08-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An immunoassay method for the detection or quantitation of an analyte suspected of being in a solution comprising: (a) combining said specimen, a first binding component, insoluble particles, and second binding component labelled with a signal generating material in a solid phase retention and separation apparatus having a sufficient pore size such that said particles are trapped within said filter yet permitting rapid passage of fluid therethrough in such a manner that an immunological reaction occurs if analyte is present in said specimen, resulting in the formation of an immunocomplex of insolublized first binding component:analyte:second labelled binding component on or within said filter means; (b) separating bound from unbound material; and (c) determining the presence and/or amount of signal produced which is correlative with the amount of analyte present in the solution.

Inventors

  • 👤 David L. Marshall

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 11:04
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/543; G01N33/54313; G01N33/536; G01N33/537; G01N33/538; G01N33/54306; G01N33/569; G01N33/56911; G01N33/56927; Y; Y10; Y10S; Y10S435/00; Y10S435/97; Y10S435/975; Y10S436/00; Y10S436/807; Y10S436/81; Y10S436/815; Y10S436/817; Y10S436/818; Y10S436/824

Claims Analysis

Total Claims: 28
Claim 1
Independent Claim 202 words
A method for detection or quantitation of an analyte in a solution comprising the steps of: (a) contacting the solution with insoluble particles having attached thereto a binding component specific for the analyte, so as to form a suspension comprising a first complex wherein the first complex comprises the analyte, the binding component and the insoluble particle; (b) applying the suspension to at least a portion of a semi-permeable membrane having interstices of dimensions relative to the insoluble particles and having a thickness such that the insoluble particles are retained throughout the thickness of the semi-permeable membrane, the portion of the semi-permeable membrane retaining the insoluble particles defining an assay zone; (c) contacting the semi-permeable membrane containing the assay zone with a labeling component capable of specifically binding to the first complex so as to form a second complex wherein the second complex comprises the first complex and the labeling component, the semi-permeable membrane permitting the labeling component which is not bound to the first complex to pass out of the assay zone; and (d) measuring the signal produced by the labeling component of the second complex as an indicator of the presence or amount of the analyte present in the solution.
Claim 2
Independent Claim 202 words
A method for detection or quantitation of an analyte in a solution comprising the steps of: (a) contacting the solution with insoluble particles having attached thereto a binding component specific for the analyte, so as to form a suspension comprising a first complex wherein the first complex comprises the analyte, the binding component and the insoluble particle; (b) applying the suspension to at least a portion of a semi-permeable membrane having interstices of dimensions relative to the insoluble particles and having a thickness such that the insoluble particles are retained throughout the thickness of the semi-permeable membrane, the portion of the semi-permeable membrane retaining the insoluble particles defining an assay zone; (c) contacting the semi-permeable membrane containing the assay zone with a labeling component capable of specifically binding to the first complex so as to form a second complex wherein the second complex comprises the first complex and the labeling component, the semi-permeable membrane permitting the labeling component which is not bound to the first complex to pass out of the assay zone; and (d) measuring the signal produced by the labeling component of the second complex as an indicator of the presence or amount of the analyte present in the solution.
Claim 3
Dependent Claim 28 words
The method of claim 1, further comprising the step of applying to the semi-permeable membrane a wash fluid capable of passing through the semi-permeable membrane after Step (c).
Claim 4
Dependent Claim 12 words
The method of claim 1, wherein the semi-permeable membrane comprises a filter.
Claim 5
Dependent Claim 23 words
The method of claim 1, wherein the semi-permeable membrane comprises a material selected from the group consisting of glass, synthetic polymers and cellulose.
Claim 6
Dependent Claim 14 words
The method of claim 1, wherein the insoluble particles comprise an inert solid phase.
Claim 7
Dependent Claim 25 words
The method of claim 5, wherein the inert solid phase comprises a material selected form the group consisting of glass, cellulose, synthetic polymer, and protein.
Claim 8
Dependent Claim 26 words
The method of claim 5, wherein the binding component is covalently bound to the solid phase in an amount sufficient to substantially coat the solid phase.
Claim 9
Dependent Claim 21 words
The method of claim 5, wherein the binding component is bound to avidin and the solid phase is bound to biotin.
Claim 10
Dependent Claim 28 words
The method of claim 1, wherein the analyte is selected from the group consisting of antigens, antibodies, proteins, bacteria, fungi, haptens, hormones, parasites, viruses, and tumor cell markers.
Claim 11
Dependent Claim 11 words
The method of claim 1, wherein the analyte is an antigen.
Claim 12
Dependent Claim 28 words
The method of claim 10, wherein the antigen is selected from the group consisting of rubella virus, HTLV, cytomegalovirus, herpes virus, Chlamydia, Neisseria gonorrhea and human chorionic gonadotropin.
Claim 13
Dependent Claim 26 words
The method of claim 1, wherein the labeling component is selected form the group consisting of enzyme, bioluminescent material, chemiluminescent material, ferromagnetic material and radioactive material.
Claim 14
Dependent Claim 12 words
The method of claim 1, wherein the labeling component is alkaline phosphatase.
Claim 15
Independent Claim 178 words
A method for detection or quantitation of an analyte in a solution comprising the steps of: (a) contacting the solution with insoluble particles having attached thereto a binding component specific for the analyte so as to form a first complex wherein the first complex comprises the analyte, the binding component and the insoluble particle and with a labeling component capable of specifically binding to the first complex so as to form a suspension comprising a second complex, wherein the second complex comprises the first complex and the labeling component; (b) applying the suspension to at least a portion of a semi-permeable membrane having interstices of dimensions relative to the insoluble particles and having a thickness such that the insoluble particles are retained throughout the thickness of the semi-permeable membrane, the semi-permeable membrane permitting the soluble labeling component which is not bound to the insoluble particles to pass therethrough; and (c) measuring the signal produced by the labeling component of the second complex as an indicator of the presence or amount of the analyte present in the specimen solution.
Claim 16
Independent Claim 178 words
A method for detection or quantitation of an analyte in a solution comprising the steps of: (a) contacting the solution with insoluble particles having attached thereto a binding component specific for the analyte so as to form a first complex wherein the first complex comprises the analyte, the binding component and the insoluble particle and with a labeling component capable of specifically binding to the first complex so as to form a suspension comprising a second complex, wherein the second complex comprises the first complex and the labeling component; (b) applying the suspension to at least a portion of a semi-permeable membrane having interstices of dimensions relative to the insoluble particles and having a thickness such that the insoluble particles are retained throughout the thickness of the semi-permeable membrane, the semi-permeable membrane permitting the soluble labeling component which is not bound to the insoluble particles to pass therethrough; and (c) measuring the signal produced by the labeling component of the second complex as an indicator of the presence or amount of the analyte present in the specimen solution.
Claim 17
Dependent Claim 28 words
The method of claim 14, further comprising the step of applying to the semi-permeable membrane a wash fluid capable of passing through the semi-permeable membrane after Step (b).
Claim 18
Dependent Claim 12 words
The method of claim 14, wherein the semi-permeable membrane comprises a filter.
Claim 19
Dependent Claim 23 words
The method of claim 14, wherein the semi-permeable membrane comprises a material selected from the group consisting of glass, synthetic polymers and cellulose.
Claim 20
Dependent Claim 14 words
The method of claim 14, wherein the insoluble particles comprise an inert solid phase.
Claim 21
Dependent Claim 25 words
The method of claim 18, wherein the inert solid phase comprises a material selected form the group consisting of glass, cellulose, synthetic polymer, and protein.
Claim 22
Dependent Claim 26 words
The method of claim 18, wherein the binding component is covalently bound to the solid phase in an amount sufficient to substantially coat the solid phase.
Claim 23
Dependent Claim 21 words
The method of claim 18, wherein the binding component is bound to avidin and the solid phase is bound to biotin.
Claim 24
Dependent Claim 28 words
The method of claim 14, wherein the analyte is selected from the group consisting of antigens, antibodies, proteins, bacteria, fungi, haptens, hormones, parasites, viruses, and tumor cell markers.
Claim 25
Dependent Claim 11 words
The method of claim 14, wherein the analyte is an antigen.
Claim 26
Dependent Claim 28 words
The method of claim 23, wherein the antigen is selected from the group consisting of rubella virus, HTLV, cytomegalovirus, herpes virus, Chlamydia, Neisseria gonorrhea, and human chorionic gonadotropin.
Claim 27
Dependent Claim 26 words
The method of claim 14, wherein the labeling component is selected form the group consisting of enzymes, bioluminescent material, chemiluminescent material, ferromagnetic material and radioactive material.
Claim 28
Dependent Claim 12 words
The method of claim 14, wherein the labeling component is alkaline phosphatase.

References Cited (Backward Citations)

US2111976A Cited
US2301717A Cited
US3011874A Cited
US3615222A Cited
US3811840A Cited
US3715192A Cited
US3645687A Cited
US3825410A Cited
US3723064A Cited
US3888629A Cited
US3867504A Cited
US3843324A Cited
US3966897A Cited
US4138474A Cited
US3966879A Cited
US4039652A Cited
US4061468A Cited
US3915647A Cited
US3979509A Cited
US4210763A Cited
US4168146A Cited
US4125372A Cited
US4180383A Cited
US4016043A Cited
US4153675A Cited
US4053284A Cited
US4094647A Cited
US4200436A Cited
US4248965A Cited
US4185084A Cited
US4200690A Cited
US4205058A Cited
US4243749A Cited
US4197361A Cited
US4233286A Cited
US4191739A Cited
US4184849A Cited
US4388296A Cited
US4298685A Cited
US4225575A Cited
US4193983A Cited
US4254222A Cited
US4271265A Cited
US4302536A Cited
US4189304A Cited
US4246339A Cited
US4361537A Cited
US4235601A Cited
US4645747A Cited
US4690908A Cited
US4301139A Cited
US4271119A Cited
US4305924A Cited
US4338094A Cited
US4299916A Cited
US4391904A Cited
US4373932A Cited
US4427769A Cited
US4323536A Cited
US4340564A Cited
US4376110A Cited
US4486530A Cited
US4366241A Cited
US4366241B1 Cited
US4429050A Cited
US4668619A Cited
US4612281A Cited
US4358535A Cited
US4358535B1 Cited
US4415700A Cited
US4613569A Cited
US4425438A Cited
US4446238A Cited
US4472498A Cited
US4446232A Cited
US4639419A Cited
US4628036A Cited
EP0088636B1 Cited
US4508831A Cited
US4681782A Cited
US4654300A Cited
US4522922A Cited
US4582792A Cited
US4454235A Cited
US4459361A Cited
US4745073A Cited
US4444880A Cited
US4424279A Cited
US4613567A Cited
US4447546A Cited
US4666863A Cited
US4496654A Cited
US4666866A Cited
US4548908A Cited
US4687732A Cited
US4673657A Cited
US4637978A Cited
US4595661A Cited
US4592894A Cited
US4717656A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1999-03-26 1999-09-25 2000-03-26 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2003-03-26 2003-09-25 2004-03-26 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2007-03-26 2007-09-25 2008-03-26 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag